If You Invested in Eikon Therapeutics, Inc. (EIKN)
Looking for the current price? See the EIKN quote & overviewWhat $1,000 or $10,000 in EIKN Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Feb 5, 2026 |
|---|---|---|---|---|
| $1,000 | — | — | — | $399 -60% |
| $10,000 | — | — | — | $3,987 -60% |
Based on real historical closing prices adjusted for stock splits, without dividends, through the latest market close. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for EIKN$1,000 Investment Over Time
EIKN vs S&P 500Year-by-Year Returns
EIKN annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2026Feb 5 to Nov 13 | $15.00 | $5.98 | -60.1% | -60.1% |
About Eikon Therapeutics, Inc.
Healthcare · NASDAQ
Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company developing medicines for serious unmet medical needs. The company operates as a drug discovery and clinical development business and reports a single operating segment focused on product candidates discovered or advanced through its proprietary technology platform. Its common stock trades on the Nasdaq Stock Market under the symbol EIKN.
Eikon’s pipeline includes multiple internally identified product candidates, including EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006. The company’s disclosed clinical work is concentrated in oncology. EIK1001 is being developed in non-small cell lung cancer, including first-line treatment of stage 4 disease. EIK1003 is being evaluated in cancer settings that include prostate cancer, breast cancer, and ovarian cancer, both as a monotherapy and in combination-based approaches. EIK1004 is a highly selective PARP1 inhibitor designed to cross the blood-brain barrier and is being studied in advanced solid tumors, including patients with active brain metastases.
The company’s business model is based on drug discovery, clinical development, and the potential advancement of product candidates through later-stage studies and regulatory pathways. As a clinical-stage biopharmaceutical issuer, Eikon’s operating disclosures center on research and development activity, clinical program progress, corporate financing, governance, and capital structure rather than commercial product sales.
Eikon is headquartered in Millbrae, California. The company completed its initial public offering in February 2026 and became a Nasdaq-listed public company with common stock registered under Section 12(b) of the Securities Exchange Act of 1934.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Eikon Therapeutics, Inc. investment returns
How much would $1,000 invested in Eikon Therapeutics, Inc. be worth today?
Limited historical data is available for EIKN. Our price data for EIKN starts on Feb 5, 2026.
Has Eikon Therapeutics, Inc. outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare EIKN performance over available time periods.
For informational and educational purposes only, not investment advice.